(AOF) – MedinCell announces the initiation of coverage of its title by the broker Tpicap Midcap with a study entitled “Maturation of the pipeline: 1st launch likely in H1-23”. The analyst recommends the value for purchase with a target price of 15 euros per share. The title of this pharmaceutical company which is developing a portfolio of long-acting injectable products gained more than 2% at the close at 7.60 euros.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.